Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
May 092012
 

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.    

Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 5-08-12). As a matter of disclosure : The author continues to be a current shareholder in the company.

Executive Officers include : Leslie J. Browne, Ph.D. President and Chief Executive Officer and John E. Thompson, Ph.D. Executive Vice President, Research and Development (https://www.senesco.com/execs.htm; obtained on 5-08-12).

“Dr. Browne has more than 30 years of experience in the pharmaceutical industry across multiple disciplines including R&D, operations and business development. Most recently he was President and CEO of Phrixus Pharmaceuticals, where he raised venture funding for the company’s Phase II clinical trial in heart failure. Previously he was President, CEO and a Director of Pharmacopeia (now part of Ligand Pharmaceuticals), where he helped transform the company into a clinical stage biopharmaceutical company with multiple development programs, and raised more than $120 million from corporate collaborations and institutional investors.

Dr. Browne also held key positions at Berlex/Schering AG, including Corporate Vice President, Berlex Laboratories, and President of Schering Berlin Venture Corporation. Earlier he was with Ciba-Geigy (now part of Novartis), where he contributed to the discovery of fadrozole, and was closely involved in the discoveries of Femara® and Diovan®, which became major products for Novartis. Dr. Browne recently served as a Director of Genelabs Technologies, which was sold to GlaxoSmithKline, and Chairman of the New Jersey Technology Council where he is currently a member of the board of directors.”  (https://www.senesco.com/execs_Leslie-J-Browne.htm; obtained on 5-08-12)

“Dr. Thompson was appointed the Company’s President and Chief Executive Officer in January 1999, and he continued in that capacity until September 1999 when he was appointed Executive Vice President of Research and Development. Dr. Thompson is the inventor of the technology that is being developed by the Company. Since July 2001, he has been the Associate Vice President, Research and from July 1990 to June 2001 he was the Dean of Science at the University of Waterloo in Waterloo, Ontario, Canada. Dr. Thompson has a Ph.D. in Biology from the University of Alberta, Edmonton, and he is a Fellow of the Royal Society of Canada. Dr. Thompson is also the recipient of a Lady Davis Visiting Fellowship, the Sigma Xi Award for Excellence in Research, the CSPP Gold Medal and the Technion Visiting Fellowship” (https://www.senesco.com/execs_John-E-Thompson.htm; obtained on 5-08-12)

The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.                                    © 2012 The Hygiology Post